Pulmonx Corporation has issued its financial outlook for 2025, projecting a gross margin of approximately 73% for the full year. The company expects total operating expenses to range between $125 million and $126 million, which includes about $21 million in non-cash stock-based compensation. In its third quarter results for 2025, Pulmonx reported worldwide revenue of $21.5 million, marking a 5% increase over the same period last year. International revenue grew by 15% year-over-year to $7.5 million, while U.S. revenue saw a 1% rise to $14.0 million. The company achieved a gross margin of 75% for the third quarter of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574254-en) on November 12, 2025, and is solely responsible for the information contained therein.